Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Baxter’

Takeda, Nanotherapeutics expand agreement for cell technology platform

Takeda, a research-based global company, and Nanotherapeutics, Inc., an integrated biopharmaceutical company, announced an agreement providing Takeda with expanded commercialization and technology access rights related to Nanotherapeutics’ Vero cell technology platform.

Bron: Pharma Biz Meer lezen »

Shire goes public with rejected $30bn Baxalta bid

Shire has confirmed that it made an all-share $30 billion offer to buy Baxalta last month, citing ’a strong strategic fit’ and the potential of a merger to ’deliver immediate value creation’. The initial approach was rejected by Illinois-based Baxalta, a recent spin-off from Baxter, which has so far declined to engage in discussions.

Bron: Meer lezen »

Baxter buys cancer portfolio for $900 million

Baxter is buying leukaemia treatment Oncaspar from Italian firm Sigma-Tau Finanziaria for $900 million as the US firm looks to bolster its oncology business. Along with the company’s Oncaspar portfolio it will be taking on a new chemical entity calaspargase pegol – a biologic in development for the treatment of acute lymphoblastic leukemia (ALL).

Bron: Meer lezen »

Pfizer acquires Baxter Men C and encephalitis vaccines for $635m

Pfizer has boosted its vaccines portfolio with a $635m deal to acquire two of Baxter’s marketed vaccines.  The pharma giant will pick up the rights to Baxter’s group C meningococcal meningitis vaccine NeisVac-C and FSME-IMMUN/TicoVac, which help protect against tick-borne encephalitis (TBE).

Bron: PMLiVE Meer lezen »

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies — one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets.

Bron: News-Medical.Net Meer lezen »

Frankrijk koopt voor gehele bevolking vaccins tegen Mexicaanse griep

Le Parisien meldt dat Frankrijk  voor de complete bevolking vaccins zal kopen. Het bevoegde crisiscentrum heeft besloten om voor 700 miljoen euro ongeveer 100 miljoen vaccins te bestellen. De bestelling zal worden geplaatst bij de vier farmaconcerns sanofi-aventis, GlaxoSmithKline, Novartis en Baxter. De vaccins worden betaald door de staat en via de sociale verzekering. Om een optimale bescherming tegen de griep te garanderen, zal elke Fransman twee vaccins ontvangen.

Tot nu toe zijn in Frankrijk 400 gevallen van de Mexicaanse griep geregistreerd.

Bron: Le Parisien

  Meer lezen »